source
- Moderna and Merck vaccine plus Keytruda cuts melanoma relapse risk by 42% in late-stage trialA late-stage adjuvant study of Moderna’s experimental melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda showed a 42% reduction in the risk of relapse or death compared with Keyt…
- Merck and Moderna’s cancer vaccine data leak precedes official Phase 3 results releaseResults from the Phase 3 trial of Moderna and Merck’s therapeutic cancer vaccine were made public on Thursday after an earlier leak of the data. The vaccine, called intismeran autogene, is being e…